•Prospective assessment of reactogenicity and disease activity after recombinant zoster vaccination in Japanese patients with inflammatory bowel disease
•Bifidobacterium animalis subsp. lactis ProSci-246 Protects Mice from DSS-induced Inflammatory Bowel Disease by Modulating the Intestinal Metabolite Profile in Mice
•Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis
•Filgotinib in the treatment of Ulcerative colitis: lessons learned from randomized trial to real-world studies
•Research progress of polyunsaturated fatty acids in inflammatory bowel disease: from mechanisms to treatment
